Novel Deiodinase 2-Selective Inhibitors—Possible Reference Substances for Regulatory <i>In Vitro</i> Tests for Endocrine Disruptors and Drugs Targeting T3-Dependent Processes
Specific DIO2 inhibitors, such as the FDA-approved drugs racecadotril and ibrutinib and the tyrosine kinase inhibitor rociletinib, might serve as a future toolbox for reversible pharmacological interference with the local provision of DIO2-generated T3 from T4 during development, tissue regeneration, and various DIO2-dependent metabolic processes. Furthermore, they can serve as reference compounds for the development and validation of regulatory <i>in vitro</i> tests. Identified FDA-approved drugs warrant a closer look at potential disturbances of local TH availability.
Authors
- Carola Seyffarth
- Yiming Zhang (ORCID: https://orcid.org/0009-0003-0487-8320)
- Eva K. Wirth (ORCID: https://orcid.org/0000-0002-0491-9941)
- Josef Köhrle (ORCID: https://orcid.org/0000-0002-9187-9078)
- Sabrina Kleissle
- Caroline Frädrich (ORCID: https://orcid.org/0000-0001-7298-844X)
- Kostja Renko (ORCID: https://orcid.org/0000-0003-2050-0961)
- Jens Peter von Kries (ORCID: https://orcid.org/0000-0003-4716-4988)
- Rajas Sane (ORCID: https://orcid.org/0000-0002-8245-8853)
- Martin Neuenschwander (ORCID: https://orcid.org/0000-0002-3114-7975)
- Anja Fischbach
- Niklas Wiese
Institutions
- Max Delbrück Center (DE)
- Federal Institute for Risk Assessment (DE)
- Humboldt-Universität zu Berlin (DE)
- Leibniz-Forschungsinstitut für Molekulare Pharmakologie (DE)
Publication Details
- Journal
- Thyroid
- Published
- 2026-03-13
- DOI
- https://doi.org/10.1177/10507256261425689
- Primary Topic
- PI3K/AKT/mTOR signaling in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00